Nano cap Cancer Genetics' (CGIX) microarray kidney cancer test delivers impressive results in a collaborative study of 188 samples with the Cleveland Clinic. The test demonstrated a sensitivity of 93% and specificity of 99%.
The company currently offers the test as a service (lab developed test or LDT).
The test is performed on kidney, either paraffin-embedded or fine needle aspirate requiring only 2 micrograms of tissue.
60,000 new cases of kidney cancer occur in the US each year with 14,000 deaths. 200,000 - 240,000 cases require annual assessment.